Radioligand therapy (RLT), also known as radiopharmaceutical therapy, is quickly becoming a major player in the oncology therapeutics space, specifically radioantibodies.
Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs have been approved by China, United States, Europe, and Australia.
Fusion proteins are engineered molecules combining domains from two or more distinct proteins into a single polypeptide chain to endow new or enhanced biological functions. In antibody research and drug development, fusion proteins often incorporate an immunoglobulin framework with targeting, signaling, or effector domains such as cytokines, enzymes, or synthetic peptides.
Antibody-drug conjugates (ADCs) rely critically on the chemical linker as the molecular bridge between the antibody and the cytotoxic payload. This component governs not only stability and pharmacokinetics but also the specificity and mechanism of payload release. Recent research describes computational and chemically innovative strategies to expand the functional and pharmacological space of linkers.
Despite comprising the largest family of druggable membrane proteins, only three G protein-coupled receptor (GPCR)-targeting antibodies have been approved. The human genome has more than 800 GPCRs, which regulate various critical physiological processes, but many GPCRs are expressed poorly, or have unknown ligands and unclear signaling pathways.
In 2025, 21 novel monoclonal antibody (mAb) drugs were approved for the first time worldwide. These approvals represent an expansion of both antibody modality and therapeutic focus, with developments in bispecifics, ADCs, long-acting formulations, and first-in-class mechanisms.
Biointron’s Q4 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in October, November, and December. This quarter, 5 novel monoclonal antibody drugs have been approved by the US, UK, and China.
Recent studies in antibody formulation highlight challenges in achieving high-concentration, stable, and patient-friendly formulations. These efforts include possible solutions in improving self-administration, global distribution without cold-chain reliance, and reducing healthcare system burdens.
Antibody discovery has traditionally relied on methods like hybridoma technology and phage display, but these approaches face increasing limitations, including low throughput, disrupted antibody chain pairing, and time-consuming workflows.
Psoriasis affects more than 100 million people around the world.The fieldof monoclonal antibody (mAb) therapeuticshas evolved from broad immunosuppressants to engineered biologics targeting key cytokine nodes in psoriatic inflammation, namely TNF-α, IL-17, and IL-23. This trend ha
Over the past few months, the biotech landscape saw venture funding of antibody companies with significant seed-to-Series D rounds across a wide range of disease areas. A key trend emerging is the diversification of antibody modalities, spanning bispecifics, antibody-drug conjugates (ADCs), radioiso
As viral threats continue to emerge and evolve, a new generation of antibody formats, derived from birds, camelids, and sharks, is gaining traction as a promising alternative for rapid, scalable, and resilient immunotherapies.A recent review by Basabrain & Alandijany (2025) describes how avian i
You can also contact us on the Scientist and Science Exchange marketplaces.
